Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.51 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.51 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.51 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.51 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9693060 | 0.89 | POLB (0.56) | POLBP2RX3P2RX2ENPP1P2RY1 | |
| SCHEMBL30888440 | 0.86 | POLB (0.51) | POLBP2RX3P2RX2ENPP1P2RY1 | |
| SCHEMBL19699271 | 0.85 | POLB (0.52) | POLBP2RX3P2RX2ENPP1P2RY1 | |
| SCHEMBL1042589 | 0.84 | POLB (0.54) | POLBP2RX3P2RX2ENPP1P2RY1 | |
| SCHEMBL19699247 | 0.83 | POLB (0.53) | POLBP2RX3P2RX2ENPP1P2RY1 | |
| SCHEMBL31685679 | 0.83 | ADORA3 (0.62) | POLBENPP1P2RY1TAS1R3TAS1R1 | |
| SCHEMBL15794921 | 0.83 | P2RX3 (0.63) | POLBP2RX3P2RX2ENPP1P2RY1 | |
| SCHEMBL9184520 | 0.82 | P2RX3 (0.62) | POLBP2RX3P2RX2ENPP1P2RY1 | |
| SCHEMBL29450536 | 0.82 | P2RX3 (0.62) | POLBP2RX3P2RX2ENPP1P2RY1 | |
| SCHEMBL31685649 | 0.82 | POLB (0.59) | POLBENPP1P2RY1DNPH1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | RNGTT, UPF1, NSUN3 | POLB 59/4885P2RX3 884/4885P2RX2 1459/4885 |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | RNGTT, UPF1, NSUN3 | POLB 60/4885P2RX3 925/4885P2RX2 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.